GlassScriptPhysician profile
Arnold S Blaustein
NPI 1497743124
$26,562.55
in general payments reported to CMS, 2019-2025
71 companies · $2,069 in 2025
The $2,069 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,341 · 2020: $1,639 · 2021: $2,036 · 2022: $10K · 2023: $2,470 · 2024: $2,605 · 2025: $2,069.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,914 · Education: $230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,914.40 |
| Education | $229.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $5,819.04 | 2021-2024 | Yescarta |
| Gilead Sciences, INC. | $2,960.96 | 2019-2022 | |
| Celgene Corporation | $1,958.06 | 2019-2025 | Reblozyl, Pomalyst, Onureg |
| Novartis Pharmaceuticals Corporation | $1,200.76 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,184.08 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Janssen Biotech, INC. | $1,180.64 | 2019-2025 | Erleada, Darzalex, Carvykti |
| Merck Sharp & Dohme LLC | $1,062.23 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $924.03 | 2019-2025 | |
| Genentech USA, INC. | $880.96 | 2019-2025 | Venclexta, Tecentriq Hybreza, Lunsumio |
| Emd Serono, INC. | $672.51 | 2019-2024 | |
| Astellas Pharma US INC | $548.90 | 2019-2025 | Xospata, Xtandi, Padcev |
| Abbvie INC. | $544.96 | 2019-2025 | Venclexta |
| Incyte Corporation | $541.95 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $480.16 | 2019-2025 | Enhertu, Injectafer, Datroway |
| E.R. Squibb & Sons, L.L.C. | $461.14 | 2019-2024 | Opdivo |
Show all 71 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arnold Blaustein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.